MUC5AC and cystic fibrosis: As a rational result, the application of KRP-109, a selective NE inhibitor, is recommended for a potential procedure to treat cystic fibrosis, because KRP-109 significantly delayed mucin degradation in the sputum of cystic fibrosis patients (Chillappagari et al., 2016).